PHR1851

Olmesartan Medoxomil

Pharmaceutical Secondary Standard; Certified Reference Material

• 別名: Olmesartan medoxomil
• 実験式（ヒル表記法）: C₂₉H₃₀N₆O₆
• CAS番号: 144689-63-4
• 分子量: 558.59
• MDL番号: MFCD00944911
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material; pharmaceutical secondary standard
• 品質水準: 300
• 認証: traceable to BP 1173; traceable to Ph. Eur. Y0001405; traceable to USP 1478367
• APIファミリー: olmesartan
• CofA: current certificate can be downloaded
• 包装: pkg of 200 mg
• アプリケーション: pharmaceutical
• フォーマット: neat
• 保管温度: -10 to -25°C
• SMILES記法: CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5
• InChI: 1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
• InChI Key: UQGKUQLKSCSZGY-UHFFFAOYSA-N
• 遺伝子情報: human ... AGTR1(185)

詳細

詳細

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Olmesartan Medoxomil is an AT₁ subtype angiotensin-II receptor antagonist used in the management of hypertension. It prevents angiotensin II from binding to the AT₁ receptors, thereby decreasing vasoconstriction.

アプリケーション

Theis pharmaceutical secondary standard can also be used as follows:

• Development and validation of an isocratic ultra-high performance liquid chromatography (UHPLC) based stability indicating method to determine olmesartan medoxomil and amlodipine besylate in combined tablet dosage forms
• Simultaneous determination of Olmesartan medoxomil and chlorthalidone by reversed phase-high performance liquid chromatography (RP-HPLC) in tablets
• Quantification of olmesartan medoxomil and its degradation products in bulk drugs and pharmaceutical formulations by using a systematic quality by design (QbD)-based reverse-phase liquid chromatography method
• Reversed phase-high performance liquid chromatographic (RP-HPLC) analysis of olmesartan medoxomil and hydrochlorothiazide in their combined tablet dosage form
• Determination of olmesartan medoxomil and amlodipine besylate in their combined tablet dosage form by absorption subtraction method, ratio subtraction with extended ratio subtraction method, dual wavelength technique, and second order derivative spectrophotometry

アナリシスノート

このような2次標準は、入手可能な場合にはUSP、EP、BPの1次標準にマルチトレーサビリティを提供します。

脚注

To see an example of a Certificate of Analysis for this material enter LRAC2529 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

安全性情報

• ピクトグラム: GHS07
• シグナルワード: Warning
• 危険有害性情報: H302 + H312 + H332
• 注意書き: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• 危険有害性の分類: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable